Cargando…
Efficacy and safety of caspofungin for patients with hepatic insufficiency
BACKGROUND: To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. METHODS: In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 patients)...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208193/ https://www.ncbi.nlm.nih.gov/pubmed/35725403 http://dx.doi.org/10.1186/s12879-022-07527-8 |
_version_ | 1784729689580896256 |
---|---|
author | Ran, Xiaoyun Wang, Pengfei Zhang, An Tang, Binfei |
author_facet | Ran, Xiaoyun Wang, Pengfei Zhang, An Tang, Binfei |
author_sort | Ran, Xiaoyun |
collection | PubMed |
description | BACKGROUND: To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. METHODS: In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 patients) treated with caspofungin from May 2018 to March 2021 in the Second Affiliated Hospital of Chongqing Medical University were enrolled. Main investigation items were as follows: sex, age, weight, duration of treatment, dosage, department, underlying diseases, risk factors for fungal infection, albumin, liver enzyme, total bilirubin, serum creatinine, estimated glomerular filtration rate. To investigate the changes of liver, kidney function tests and efficacy during the treatments of caspofungin. Patients were divided into three groups according to the duration of treatment of caspofungin:1-week group, 2-week group and 3-week group, respectively. RESULTS: In the three groups, albumin, liver enzyme levels, total bilirubin and serum creatinine, estimated glomerular filtration rate had no significant difference (P > 0.05). The efficacy of different Child–Pugh scores and different duration of treatment was also significantly different (P > 0.05). CONCLUSIONS: Caspofungin is well tolerated and highly effective. And it will not exacerbate the hepatic and renal function when administered with the not-reducing dose, which indicate the clinical application value of caspofungin. Besides, extending the treatment duration has little effect on improving the efficacy of caspofungin. The drug should be withdrawn timely according to the patients’ clinical condition in order to reduce the adverse reactions and economic burden. |
format | Online Article Text |
id | pubmed-9208193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92081932022-06-21 Efficacy and safety of caspofungin for patients with hepatic insufficiency Ran, Xiaoyun Wang, Pengfei Zhang, An Tang, Binfei BMC Infect Dis Research BACKGROUND: To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. METHODS: In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 patients) treated with caspofungin from May 2018 to March 2021 in the Second Affiliated Hospital of Chongqing Medical University were enrolled. Main investigation items were as follows: sex, age, weight, duration of treatment, dosage, department, underlying diseases, risk factors for fungal infection, albumin, liver enzyme, total bilirubin, serum creatinine, estimated glomerular filtration rate. To investigate the changes of liver, kidney function tests and efficacy during the treatments of caspofungin. Patients were divided into three groups according to the duration of treatment of caspofungin:1-week group, 2-week group and 3-week group, respectively. RESULTS: In the three groups, albumin, liver enzyme levels, total bilirubin and serum creatinine, estimated glomerular filtration rate had no significant difference (P > 0.05). The efficacy of different Child–Pugh scores and different duration of treatment was also significantly different (P > 0.05). CONCLUSIONS: Caspofungin is well tolerated and highly effective. And it will not exacerbate the hepatic and renal function when administered with the not-reducing dose, which indicate the clinical application value of caspofungin. Besides, extending the treatment duration has little effect on improving the efficacy of caspofungin. The drug should be withdrawn timely according to the patients’ clinical condition in order to reduce the adverse reactions and economic burden. BioMed Central 2022-06-20 /pmc/articles/PMC9208193/ /pubmed/35725403 http://dx.doi.org/10.1186/s12879-022-07527-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ran, Xiaoyun Wang, Pengfei Zhang, An Tang, Binfei Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title_full | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title_fullStr | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title_full_unstemmed | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title_short | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
title_sort | efficacy and safety of caspofungin for patients with hepatic insufficiency |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208193/ https://www.ncbi.nlm.nih.gov/pubmed/35725403 http://dx.doi.org/10.1186/s12879-022-07527-8 |
work_keys_str_mv | AT ranxiaoyun efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT wangpengfei efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT zhangan efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT tangbinfei efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency |